BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30592483)

  • 41. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity Score-Matched Analysis.
    Sim DS; Jeong MH; Ahn Y; Kim YJ; Chae SC; Hong TJ; Seong IW; Chae JK; Kim CJ; Cho MC; Rha SW; Bae JH; Seung KB; Park SJ;
    Circ Cardiovasc Interv; 2016 Sep; 9(9):. PubMed ID: 27582112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis.
    Fahrni G; Wolfrum M; De Maria GL; Banning AP; Benedetto U; Kharbanda RK
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27451466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.
    Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E
    BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry.
    Ge Z; Baber U; Claessen BE; Farhan S; Chandrasekhar J; Li SX; Sartori S; Kini AS; Rao SV; Weiss S; Henry TD; Vogel B; Sorrentino S; Faggioni M; Kapadia S; Muhlestein B; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):E112-E119. PubMed ID: 30351514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.
    Geisler T; Droppa M; Gawaz M; Steinhubl SR; Bertrand ME; Lincoff AM; Cequier AR; Desmet W; Rasmussen LH; Hoekstra JW; Bernstein D; Deliargyris EN; Mehran R; Stone GW
    Catheter Cardiovasc Interv; 2016 Aug; 88(2):174-81. PubMed ID: 26332193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
    Sibbing D; Gross L; Trenk D; Jacobshagen C; Geisler T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Parma R; Felix SB; Neumann FJ; Hausleiter J; Baylacher M; Koltowski L; Mehilli J; Huber K; Huczek Z; Aradi D; Massberg S;
    Eur Heart J; 2018 Aug; 39(29):2749-2758. PubMed ID: 29912422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China.
    Xu H; Yang Y; Wang C; Yang J; Li W; Zhang X; Ye Y; Dong Q; Fu R; Sun H; Yan X; Gao X; Wang Y; Jia X; Sun Y; Wu Y; Zhang J; Zhao W; Sabatine MS; Wiviott SD;
    JAMA Netw Open; 2020 Oct; 3(10):e2021677. PubMed ID: 33095249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of arterial access site selection on outcomes in primary percutaneous coronary intervention: are the results of randomized trials achievable in clinical practice?
    Mamas MA; Ratib K; Routledge H; Neyses L; Fraser DG; de Belder M; Ludman PF; Nolan J;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):698-706. PubMed ID: 23769648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative.
    Wang TY; Chen AY; Peterson ED; Becker RC; Gibler WB; Ohman EM; Roe MT
    Eur Heart J; 2008 May; 29(9):1103-9. PubMed ID: 18353757
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
    Bossard M; Granger CB; Tanguay JF; Montalescot G; Faxon DP; Jolly SS; Widimsky P; Niemela K; Steg PG; Natarajan MK; Gao P; Fox KAA; Yusuf S; Mehta SR
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29101117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population.
    Wang H; Liang Z; Li Y; Li B; Liu J; Hong X; Lu X; Wu J; Zhao W; Liu Q; An J; Li L; Pu F; Ming Q; Han Y
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28083915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    Bosch X; Marrugat J; Sanchis J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD002130. PubMed ID: 24203004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
    Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
    J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    Bosch X; Marrugat J; Sanchis J
    Cochrane Database Syst Rev; 2013 Oct; (10):CD002130. PubMed ID: 24136036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial.
    Madhavan MV; Généreux P; Kirtane AJ; Xu K; Witzenbichler B; Mehran R; Stone GW
    Eur Heart J Acute Cardiovasc Care; 2017 Oct; 6(7):650-658. PubMed ID: 26124455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Eccleston D; Andrianopoulos N; Farouque O; Duffy SJ; Brennan A; Reid C; Clark DJ; Ajani AE;
    Intern Med J; 2015 Oct; 45(10):1032-7. PubMed ID: 26013065
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coronary artery bypass graft surgery provides better survival in patients with acute coronary syndrome or ST-segment elevation myocardial infarction experiencing cardiogenic shock after percutaneous coronary intervention: a propensity score analysis.
    Chiu FC; Chang SN; Lin JW; Hwang JJ; Chen YS
    J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1326-30. PubMed ID: 19660378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of Initial Revascularization Versus Medical Therapy Alone in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing an Invasive Strategy.
    Wijeysundera HC; Sidhu MS; Bennell MC; Qiu F; Ko DT; Knudtson ML; Tu JV; Boden WE
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27418612
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
    Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
    Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.